Over 1000 children annually receive parenteral nutrition (PN) for at least 4 weeks and about 70 go on to receive home PN each year (1) . Most of these children have biochemical abnormalities of liver function at some point during the course of their treatment although only a minority develop life-threatening intestinal failure associated liver disease (IFALD). The onset of IFALD is an indication for referral for consideration of small-bowel transplantation (SBTx). The decision to recommend SBTx depends on many factors, but one of the key issues is estimating the severity of IFALD and the possibility of clinical deterioration.
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We reviewed our database containing clinical information on all children undergoing a formal transplant assessment from 1990 until 2009 to ascertain the number with IFALD. Bilirubin concentrations recorded at the time of SBTx assessment have been used to assign a severity category for IFALD based on the criteria from Xth International Symposium of Small Bowel transplantation (2) . Overall 123 children were considered stable and were not offered SBTx, 37 subsequently died of causes other than IFALD. Of the 77 children (31% of those referred) with no IFALD or Type 1 IFALD, 13 were transplanted (for loss of access for feeding catheters). Of the 118 children with type 3 + IFALD, 32 died on the transplant waiting list, 42 received a transplant. Thirty children were not offered SBTx because of contra-indications and 28 of those children died. Fifty-four children (21%) had less severe IFALD (types 2 and 3) at the time of referral and the outcome for them was: 7 died on transplant waiting list; 21 received a transplant. 16 showed an improvement in IFALD and were not put on the waiting list for transplant. The 5-year survival for SBTx in patients with no IFALD or type 1 IFALD, is now 80 %. However, the largest group of referred patients had type 3 + IFALD and despite the increased morbidity and mortality of SBTx in the context of liver failure, 118 children (47%) were already in that condition at the time of referral. These data suggest that type 2 IFALD can progress rapidly to types 3 and 3 + IFALD and that patients would benefit from earlier referral to a transplant centre.
